Remel, Inc recalls

Remel, Inc. is recalling one lot of Yeastone Broth used in antibiotic susceptibility testing of mycological clinical specimens. The affected lot did not meet specifications and may report false susceptibility to Azole-family antifungal agents. No injuries have been reported.

Moderate·FDA·Nov 3, 2026

Certain lots of the Remel (Thermo Fisher Diagnostics) Neisseria meningitidis Group C 2 mL test, product R30166901, did not perform as its instructions require. The test did not return a positive result with a reference control strain within 60 seconds. About 26 units were distributed nationwide, and no injuries have been reported.

Moderate·FDA·Aug 19, 2026

Remel, Inc. is recalling certain 100mm and 150mm GC Agar Base lab culture plates because some strains of gonorrhea bacteria may grow poorly or not at all on them. The recall covers specific lot numbers and was distributed in the US, Canada, Singapore, and the United Kingdom. No injuries have been reported.

Moderate·FDA·Jul 8, 2026

Remel's Yeastone Broth (11ML, 10/BOX, model YY3462) may give wrong results when labs use it to test how fungi respond to antifungal medicines. If a lab doesn't catch the bad result during its own quality checks, doctors might delay treatment or switch to a different antifungal drug unnecessarily.

Moderate·FDA·Apr 22, 2026

Remel's Campy CVA Medium (lot R01272, UDI 848838001055) is not reliably recovering Campylobacter Jejuni bacteria during laboratory culture testing. Customers reported low to no bacterial growth on this specific lot, which could lead to missed or delayed diagnoses.

Moderate·FDA·Mar 4, 2026

Products may contain contamination, which may result in a darker or brown media color.

FDA·Dec 3, 2025